These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1139592)

  • 1. [The hepatotoxic action of erythromycin (author's transl)].
    Svejda J; Richter J
    Cas Lek Cesk; 1975 Mar; 114(13):407-10. PubMed ID: 1139592
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of group A streptococcal pharyngitis: a randomized controlled study of twice-daily erythromycin ethylsuccinate versus erythromycin estolate.
    Ginsburg CM; McCracken GH; Steinberg JB; Crow SD; Dildy BF; Lancaster K; Olsen K
    Pediatr Infect Dis; 1982; 1(6):384-7. PubMed ID: 6761656
    [No Abstract]   [Full Text] [Related]  

  • 3. [Controlled study of the liver-protective effect of cycloxilic acid in a form of iatrogenic liver disease].
    Neuman M; Fluteau G
    Clin Ter; 1978 Nov; 87(3):243-64. PubMed ID: 380876
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythromycin therapy for group A streptococcal pharyngitis. Results of a comparative study of the estolate and ethylsuccinate formulations.
    Ginsburg CM; McCracken GH; Crow SD; Dildy BR; Morchower G; Steinberg JB; Lancaster K
    Am J Dis Child; 1984 Jun; 138(6):536-9. PubMed ID: 6372437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
    Keeffe EB; Reis TC; Berland JE
    Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of erythromycin ethyl succinate, stearate and estolate treatments of group A streptococcal infections of the upper respiratory tract.
    Janicki RS; Garnham JC; Worland MC; Grundy WE; Thomas JR
    Clin Pediatr (Phila); 1975 Dec; 14(12):1098-107. PubMed ID: 1104241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptococcal pharyngitis therapy. A comparison of two erythromycin formulations.
    Derrick CW; Dillon HC
    Am J Dis Child; 1979 Nov; 133(11):1146-8. PubMed ID: 389036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA begins proceedings to remove erythromycin estolate from market.
    FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythromycin estolate-induced hepatitis. Ultrastructural study of liver.
    Gafter U; Mandel EM; Weiss S; Djaldetti M
    N Y State J Med; 1979 Jan; 79(1):87-9. PubMed ID: 282477
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythromycin estolate impairs the mitochondrial and microsomal calcium homeostasis: correlation with hepatotoxicity.
    Richelmi P; Baldi C; Manzo L; Berte F; Martino AP; Mirabelli F; Bellomo G
    Arch Toxicol Suppl; 1984; 7():298-302. PubMed ID: 6595996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-benefit equation for erythromycin estolate.
    LeBel M
    Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788
    [No Abstract]   [Full Text] [Related]  

  • 12. [On the article of J. Buchanec and V. Kdrajnák: Lesions of the liver during therapy with erythromycin in 3 children].
    Rouzica M; Filipová K
    Cesk Pediatr; 1975 Jan; 30(1-2):71. PubMed ID: 1132045
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cholestatic hepatitis caused by erythromycin estolate].
    García Monzón C; Noguerado A; Hidalgo S; Escudero V
    Rev Clin Esp; 1985 Nov; 177(8):420-1. PubMed ID: 3836470
    [No Abstract]   [Full Text] [Related]  

  • 14. [Surgical and drug treatment of infection of the extremities].
    Marques EF
    Hospital (Rio J); 1969 Jun; 75(6):2099-106. PubMed ID: 5311465
    [No Abstract]   [Full Text] [Related]  

  • 15. Erythromycin propionate and estolate.
    Farre M
    Lancet; 1988 Jul; 2(8601):45. PubMed ID: 2898648
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Staphylococcus aureus infections in children in office practice.
    Disney FA; Pichichero ME
    Am J Dis Child; 1983 Apr; 137(4):361-4. PubMed ID: 6600877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical effects of erythrocin for the infectious diseases of the mouth].
    Suzuki S; Noshiro T; Kuga Y; Fukuda J; Hida J
    Shikai Tenbo; 1978; 52(3):533-9. PubMed ID: 295915
    [No Abstract]   [Full Text] [Related]  

  • 18. The usefulness of erythromycin in paediatrics.
    Gołeebiowska H; Prokopczyk J; Pawluch D; Nowakowska K; Bozkowa K
    J Chemother; 1989 Jul; 1(4 Suppl):689-90. PubMed ID: 16312594
    [No Abstract]   [Full Text] [Related]  

  • 19. A study of erythromycin activity in vivo.
    Gomez Lus R; Rubio Calvo MC; Davis PE; Larrad L; Gomez G; Guillen Agudo G; Blay V
    J Int Med Res; 1980; 8 Suppl 2():24-35. PubMed ID: 7429003
    [No Abstract]   [Full Text] [Related]  

  • 20. A prospective study on the incidence of liver function abnormalities in children receiving erythromycin estolate, erythromycin ethylsuccinate or penicillin V for treatment of pneumonia.
    Ginsburg CM
    Pediatr Infect Dis; 1986; 5(1):151-3. PubMed ID: 3080735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.